Sunday, October 2, 2022

Industry Corruption in Systematic Review for Injectable Antipsychotics

1
Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.

Many Service Users Interested in Decreasing Antipsychotic Use with Professional Help

8
New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.

Antipsychotics Often Prescribed Without Informed Consent

25
New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.

Antipsychotics Worsen Cognitive Functioning in First-Episode Psychosis

1
Withholding antipsychotics may be beneficial for memory, the researchers write.

Manufacturer of Tardive Dyskinesia (TD) Drugs Finds TD Emotionally Devastating

14
“Patients expressed feeling unaccepted by society or uncomfortable in their own skin… A few indicated that they would rather be dead than have tardive dyskinesia.”

Antipsychotics Linked to Increased Breast Cancer Risk

0
Long-term exposure to prolactin-increasing antipsychotics increases the odds of developing breast cancer.

New Rating Tool for Tapering Antidepressants and Antipsychotics

1
Researchers developed a rating scale to better assess service users’ experiences tapering antidepressant and/or antipsychotic medication.

Antipsychotics Increase Risk of Dementia; New Research Illuminates Why

15
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

Tapered Antipsychotic Withdrawal Mitigates Risk of Psychotic Symptoms

15
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.

Sudden Antipsychotic Withdrawal—Not Low Dose—Leads to Relapse

13
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

Antipsychotic Adherence Research Overlooks Key Information

17
Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.
Question mark inside a maze in the shape of human head.

New Study: The Clinical High Risk for Psychosis (CHR-P) Model Is Flawed

3
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Doctor and patient

Barriers to Shared Decision Making in the Prescription of Antipsychotics

26
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.

Anticholinergic Medications Linked to Cognitive Impairment in Schizophrenia

3
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.

Keys to Successful Discontinuation of Antipsychotic Medication

6
Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

The BBC, Harrow, and a Public Left in the Dark

77
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years

61
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...

92
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia

67
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

Anticholinergic Drugs Increase Risk of Cognitive Decline

10
A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
antipsychotic drugs

Antipsychotic Augmentation Increases Risk of Death

7
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes

17
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

Very Slow Taper Best for Antipsychotic Discontinuation

12
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

170
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes

4
A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

Follow Us

31,706FansLike
30,590FollowersFollow
0SubscribersSubscribe